Life expectancy standardized mortality ratios and causes of death in six rheumatic diseases in Hong Kong China.код для вставкиСкачать
ARTHRITIS & RHEUMATISM Vol. 63, No. 5, May 2011, pp 1182–1189 DOI 10.1002/art.30277 © 2011, American College of Rheumatology Life Expectancy, Standardized Mortality Ratios, and Causes of Death in Six Rheumatic Diseases in Hong Kong, China C. C. Mok,1 C. L. Kwok,2 L. Y. Ho,1 P. T. Chan,1 and S. F. Yip2 Objective. To examine the life expectancy, standardized mortality ratios (SMRs), and causes of death in 6 groups of patients from Hong Kong with different rheumatic diseases. Methods. Patients with a diagnosis of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic vasculitis (SV), or systemic sclerosis (SSc) registered in 37 public hospitals between 1999 and 2008 were identified in the hospital registry. SMRs were calculated by comparing the mortality rate in patients with each disease with that in the general population. Life expectancy was calculated by abridged life-table analysis, and the causes of death were compared. Results. In 2008, data on 8,367 RA, 5,243 SLE, 2,154 AS, 1,636 SV, 778 PsA, and 449 SSc patients were available in our registry. The age- and sex-adjusted SMRs were highest for SLE (5.25 [95% confidence interval 4.79–5.70]), SSc (3.94 [95% confidence interval 3.20–4.68]), and SV (2.64 [95% confidence interval 2.36–2.93]). In female patients, the loss in life expectancy was greatest for SSc (34.1 years), SV (19.3 years), and SLE (19.7 years). In male patients, the loss in life expectancy was highest for SV (28.3 years), SLE (27 years), and SSc (16 years). There were 2,486 deaths during the study period (1999–2008), and the principal causes were infections (28%), cardiovascular complications (18%), cancer (16%), and disease activity (7%). Infection was the leading cause of death in SLE, RA, AS, and PsA, whereas deaths from disease-related activity and cardiovascular complications were most frequent in SSc. Cancer was the most common cause of death in SV. Conclusion. Our findings indicate that patients with SLE, RA, AS, PsA, SV, and SSc have increased mortality rates and reduced life expectancy. SLE has the highest adjusted SMR, and female SSc patients have the greatest loss in life expectancy. Infection is the leading cause of death, followed by cardiovascular complications and malignancies. Rheumatic diseases are chronic multisystemic medical illnesses that are associated with significant mortality and morbidity. Organ dysfunction as a result of disease involvement is a major cause of reduced survival. Examples are renal failure in patients with systemic lupus erythematosus (SLE) and systemic vasculitis (SV), pulmonary hypertension and interstitial lung fibrosis causing cardiorespiratory failure in patients with systemic sclerosis (SSc), and extraarticular complications, such as heart, lung, and renal diseases, in patients with inflammatory arthritides, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). In addition to disease-related complications, adverse events related to treatment may aggravate the risk of mortality. Immunosuppressive therapies for various rheumatic diseases increase the incidence of common bacterial and viral, as well as opportunistic, infections and other long-term adverse effects, such as liver fibrosis, malignancies, premature menopause, and osteoporotic fractures. Common to all of these rheumatic disorders is chronic inflammation in the joints and the visceral organs. Chronic inflammation is associated with the persistent elevation of levels of proinflammatory markers, such as tumor necrosis factor ␣, interleukin-6 (IL-6), and C-reactive protein (CRP), which are associated with an increased risk of atherosclerosis and arterial thrombosis (1–3). The standardized incidence ratios of coronary heart disease and cerebrovascular disease (stroke) are increased in patients with RA, SLE, AS, and PsA (4–7), and these cardiovascular complications are major causes of death, second to infection. 1 C. C. Mok, MD, FRCP, L. Y. Ho, MBChB, MRCP, P. T. Chan, MBBS, MRCP: Tuen Mun Hospital, Hong Kong, China; 2C. L. Kwok, BSc, S. F. Yip, PhD: University of Hong Kong, Hong Kong, China. Address correspondence to C. C. Mok, MD, FRCP, Department of Medicine, Tuen Mun Hospital, Tsing Chung Koon Road, New Territories, Hong Kong, China. E-mail: email@example.com. Submitted for publication September 15, 2010; accepted in revised form January 25, 2011. 1182 LIFE EXPECTANCY, SMRs, AND CAUSES OF DEATH IN RHEUMATIC DISEASES The cumulative survival rate of an inception cohort of patients who were diagnosed as having SLE between 1991 and 2003 in our geographic area was 92% 5 years after disease onset and 83% 10 years after disease onset (8). The unadjusted standardized mortality ratio (SMR) for our local SLE patients in the year 2006 was estimated to be 2.2 (95% confidence interval [95% CI] 0.7–6.7) (9). However, data on the life expectancy of SLE patients and on mortality rates in other non-SLE rheumatic diseases in our locality are unavailable. This prompted the current study, which used the hospital registry system and population census data to analyze the life expectancy and SMRs for 6 diseases that are commonly encountered in rheumatologic practice. The causes of death in patients with these diseases were also evaluated and compared. PATIENTS AND METHODS Data source. Hong Kong is a small city situated in the southern part of China. In the year 2009, it had an estimated population of 7 million, 95% of whom were ethnic Chinese. All citizens of Hong Kong are entitled to receive heavily government-subsidized public medical services by paying a nominal fee for medical consultations in hospitals and outpatient clinics. These medical services are provided by 37 hospitals run by the Hospital Authority, and they account for ⬎90% of the medical care provided in Hong Kong. The numbers of patients with International Classification of Diseases, Ninth Revision (ICD-9), diagnostic codes for SLE, RA, AS, PsA, SV, and SSc who were registered and treated in 37 Hospital Authority hospitals between 1999 and 2008 were retrieved using the Clinical Data Analysis and Reporting System (CDARS). This central system captures data on both patients treated in outpatient clinics and inpatient hospital admissions. Patients with these disease codes who died during the specified period were identified using the same system. The causes of death, which were recorded in the death registry according to ICD-9 codes, were evaluated and compared across the 6 rheumatic diseases. Determination of SMRs. The SMR was used to compare the mortality risk of patients with any of the 6 rheumatic diseases to that of the general population of Hong Kong. SMR and its asymptotic 95% CI were calculated as follows: SMR ⫽ 冉 95% CI ⫽ SMR ⫺ 1.96 ⫻ O E 冑O E , SMR ⫹ 1.96 ⫻ 冑O E 冊 where O is the observed number of deaths in the study population and E is the expected number of deaths (10). For each of the 6 rheumatic diseases, the expected number of deaths was calculated as the total number of person-years contributed by the study population (i.e., patients with that disease) multiplied by the mortality rate of the general population. The age- and sex-adjusted SMRs were 1183 calculated similarly, except that the expected number of deaths was stratified by age and sex. The size of the general population and the mortality rate in the general population from 1999 to 2008 were obtained from the Census and Statistics Department of the Hong Kong government, which maintains population census data from the years 1996, 2001, and 2006, with annual adjustments according to birth, death, and immigration/emigration status. The mean values of crude death rates over 10 years were used in the SMR analysis described above. Life expectancy analysis. Life expectancy for patients with each of the 6 rheumatic diseases was estimated by standard single-decrement life-table analysis as described by Preston et al (11), using CDARS prevalence and death data and Hong Kong population census data for 1999–2008. The following assumptions were made in the construction of period life tables for each sex and disease. First, the number of patients and the number of deaths for each age group in a given year were assumed to be independent of those in the subsequent year, and second, deaths were assumed to be symmetrically distributed in each age group. Under the first assumption, the age-specific death rates mx could be estimated by the maximum likelihood estimator for binomial distribution parameter, given by mx ⫽ d x1⫹d x2⫹· · · ⫹d xk n x1 ⫹ n x2 ⫹ · · · ⫹n xk where dkx is the number of deaths for age group x in the kth year and nkx is the number of patients for age group x in the kth year (12). Although the second assumption might not be valid in patients younger than 5 years old, this did not affect the results of the life expectancy analysis, since no deaths were observed in age groups 0–1 year and 1–4 years for patients with the 6 diseases that were studied. Analysis of the causes of death. The principal causes of death, as coded by the attending physician in the death registry of the CDARS, were obtained for patients with the 6 diseases who died between 1999 and 2008. These were grouped under the following categories: infections, malignancies, cardiovascular and circulatory complications, cerebrovascular complications, gastrointestinal complications, hepatic complications, respiratory causes (excluding infections), renal failure, trauma and poisoning (including suicide), and related to rheumatic disease activity but with unspecified exact causes. Statistical analysis. Unless stated otherwise, values are expressed as the mean ⫾ SD. Comparison of the frequencies of deaths due to various causes across different rheumatic diseases was performed by the chi-square test. P values less than 0.05 (2-tailed) were considered significant. All statistical analyses were performed using SPSS software, version 11.5 for Windows XP. RESULTS Demographic characteristics of the patients. Table 1 shows the age, sex, and cumulative number of patients with the diagnostic codes for each of the 6 rheumatic diseases captured by the CDARS at the 1184 MOK ET AL Table 1. Demographic characteristics of the patients with each rheumatic disease* SLE (n ⫽ 5,243) Women, no. (%) Men, no. (%) Ratio of female to male patients Age, mean ⫾ SD years 4,782 (91) 461 (9) 10.4:1 44.3 ⫾ 15.1 RA (n ⫽ 8,367) 6,657 (80) 1,710 (20) 3.9:1 56.4 ⫾ 17.0 AS (n ⫽ 2,154) 369 (17) 1,785 (83) 1:4.8 46.4 ⫾ 14.9 PsA (n ⫽ 778) SSc (n ⫽ 449) 354 (46) 424 (54) 1:1.2 382 (85) 67 (15) 5.7:1 51.7 ⫾ 13.2 51.8 ⫾ 17.2 SV (n ⫽ 1,636) 1,021 (62) 615 (38) 1.7:1 51.4 ⫾ 19.4 * Data are for all living patients with records in the hospital registry at the beginning of 2008. SLE ⫽ systemic lupus erythematosus; RA ⫽ rheumatoid arthritis; AS ⫽ ankylosing spondylitis; PsA ⫽ psoriatic arthritis; SSc ⫽ systemic sclerosis; SV ⫽ systemic vasculitis. beginning of 2008 (including all new and old patients and living patients who were lost to followup). There were 8,367 RA patients, 5,243 SLE patients, 2,154 AS patients, 1,636 SV patients, 778 PsA patients, and 449 SSc patients. Their mean ages in 2008 were 44.3 years for the SLE patients, 56.4 years for the RA patients, 46.4 years for the AS patients, 51.7 years for the PsA patients, 51.8 years for the SSc patients, and 51.4 years for the SV patients. Patients with SLE, SSc, and RA were predominantly female, whereas patients with AS were predominantly male. There were slightly more women than men with SV, and the sex distribution was roughly equal for PsA. SMRs. The SMRs for the 6 rheumatic diseases within the study period are shown in Table 2. The ageand sex-adjusted SMR was highest for SLE (5.25 [95% CI 4.79–5.70]), followed by SSc (3.94 [95% CI 3.20– 4.68]), SV (2.64 [95% CI 2.36–2.93]), AS (1.87 [95% CI 1.61–2.13]), RA (1.68 [95% CI 1.59–1.77]), and PsA (1.59 [95% CI 1.16–2.03]). For women, the age-adjusted SMRs, in descending order, were as follows: SLE (5.59 [95% CI 5.07–6.12]), SSc (4.32 [95% CI 3.45–5.20]), SV (2.66 [95% CI 2.27–3.05]), PsA (1.96 [95% CI 1.14– 2.77]), RA (1.72 [95% CI 1.61–1.82]), and AS (1.38 [95% CI 0.74–2.02]). The corresponding values for men were SLE (3.94 [95% CI 3.08–4.80]), SV (2.62 [95% CI 2.20–3.05]), SSc (2.59 [95% CI 1.32–3.87]), AS (1.94 [95% CI 1.65–2.22]), RA (1.59 [95% CI 1.42–1.76]), and PsA (1.40 [95% CI 0.89–1.90]). The mortality rates for patients with these rheumatic diseases were 59–425% higher than those of the age- and sex-matched general population. Of note, the adjusted SMR for SLE patients was much higher than the unadjusted value (5.25 versus 2.63), indicating a much greater impact of mortality on the younger population with this disease. Results of life expectancy analysis. Figures 1 and 2 show the life expectancy curves for the 6 rheumatic diseases, stratified according to sex, in comparison with the life expectancy for the general population within the same time period. The life expectancy curve for male patients with PsA could not be plotted because of the absence of deaths in the older age groups. For female patients, the loss in life expectancy at the time of birth compared with the general population was greatest for patients with SSc (34.1 years), followed by SV (19.3 years), SLE (19.7 years), RA (6.9 years), PsA (6.5 years), and AS (1.2 years). For male patients, the loss in life expectancy was greatest for patients with SV (28.3 years), followed by SLE (27.0 years), SSc (16.0 years), AS (7.0 years), and RA (5.2 years). The loss in life years appeared to be greatest for younger patients (particularly patients with an age at onset of disease of younger than 40 years). Mortality rates and causes of death. Between January 1999 and December 2008, there were 2,486 deaths (1,705 [69%] women). The distribution of deaths for each of the underlying rheumatic diseases was 52% RA, 21% SLE, 13% SV, 8% AS, 4% SSc, and 2% PsA. Table 2. Standardized mortality ratios (SMRs) for the 6 rheumatic diseases within the study period* Women Men All Age-adjusted SMR (women) Age-adjusted SMR (men) Age- and sex-adjusted SMR SLE RA AS PsA SSc SV 2.88 (2.61–3.15) 4.00 (3.13–4.87) 2.63 (2.41–2.86) 5.59 (5.07–6.12) 3.94 (3.08–4.80) 5.25 (4.79–5.70) 5.05 (4.73–5.37) 4.97 (4.43–5.50) 4.58 (4.33–4.83) 1.72 (1.61–1.82) 1.59 (1.42–1.76) 1.68 (1.59–1.77) 2.07 (1.11–3.03) 2.86 (2.44–3.28) 3.07 (2.64–3.50) 1.38 (0.74–2.02) 1.94 (1.65–2.22) 1.87 (1.61–2.13) 2.76 (1.61–3.91) 2.27 (1.44–3.10) 2.50 (1.81–3.19) 1.96 (1.14–2.77) 1.40 (0.89–1.90) 1.59 (1.16–2.03) 8.55 (6.82–10.28) 6.53 (3.33–9.73) 7.29 (5.93–8.65) 4.32 (3.45–5.20) 2.59 (1.32–3.87) 3.94 (3.20–4.68) 6.67 (5.70–7.65) 6.82 (5.70–7.93) 6.47 (5.77–7.18) 2.66 (2.27–3.05) 2.62 (2.20–3.05) 2.64 (2.36–2.93) * Values are the SMR (95% confidence interval). See Table 1 for other definitions. LIFE EXPECTANCY, SMRs, AND CAUSES OF DEATH IN RHEUMATIC DISEASES 1185 The mean ⫾ SD age at the time of death was 52.0 ⫾ 17 years for SLE patients, 75.1 ⫾ 11.0 years for RA patients, 68.6 ⫾ 17.0 years for SV patients, 69.5 ⫾ 11.4 years for AS patients, 67.2 ⫾ 13.6 years for PsA patients, and 64.5 ⫾ 15.2 years for SSc patients. Table 3 shows the causes of death according to the ICD-9 codes recorded in the death registry. The principal causes of death were, in descending order of frequency, infections (28%), cardiovascular/cerebrovascular complications (18%), cancer (16%), disease activity (7%), renal failure (6%), pulmonary causes (6%), gastrointestinal and hepatic complications (4%), and accidents, injury, or poisoning (including suicide) (0.7%). The cause of death was recorded as “other” in 4% of the cases, and the cause of death was missing for 9%. Infection was the leading cause of death in SLE, Figure 2. Life expectancy curves for female patients (A) and male patients (B) with ankylosing spondylitis (circles), psoriatic arthritis (squares), or systemic vasculitis (triangles), as compared to the life expectancy of the general population (diamonds) from 1999 to 2008. The life expectancy curve for male patients with PsA could not be plotted because of the absence of deaths in the older age groups. RA, AS, and PsA, whereas disease-related and cardiovascular complications were the most frequent causes of death in patients with SSc. Cancer was the most frequent cause of death in patients with SV, while renal failure was the most frequent cause of death in SLE and RA. DISCUSSION Figure 1. Life expectancy curves for female patients (A) and male patients (B) with rheumatoid arthritis (circles), systemic lupus erythematosus (squares), or systemic sclerosis (triangles), as compared to the life expectancy of the general population. This is the first study to examine the mortality statistics for different rheumatic disorders in a large number of patients from the Hong Kong central hospital registry. We demonstrated that the age- and sexadjusted mortality rates in patients with RA, SLE, AS, PsA, SSc, and SV were significantly higher than those in 1186 MOK ET AL Table 3. Causes of death in the patients with rheumatic diseases (January 1999 to December 2008)* Cause of death SLE (n ⫽ 514) RA (n ⫽ 1,289) AS (n ⫽ 197) PsA (n ⫽ 51) SSc (n ⫽ 110) SV (n ⫽ 325) Total (n ⫽ 2,486) Infection Septicemia Pneumonia Soft tissue Tuberculosis Other Cancer Cardiovascular Coronary heart disease Heart failure Arrhythmia Pulmonary embolism Pulmonary hypertension Other Cerebrovascular Gastrointestinal Hepatic Respiratory system Obstructive airway disease Bronchiectasis Pulmonary fibrosis Other Renal failure Poisoning/injury Disease activity Other Unknown (missing data) 114 (22) 25 (5) 72 (14) 3 (0.6) 9 (1.8) 5 (1) 61 (12) 53 (10) 29 (6) 7 (1.4) 4 (0.8) 2 (0.4) 5 (1) 6 (1.2) 33 (6.4) 24 (4.7) 7 (1.4) 9 (1.8) 3 (0.6) 0 (0) 4 (0.8) 2 (0.4) 44 (9) 7 (1.4) 110 (21) 13 (2.5) 39 (8) 442 (34) 61 (5) 324 (25) 3 (0.2) 10 (0.8) 44 (3) 175 (14) 160 (12) 89 (7) 45 (3.5) 10 (0.8) 3 (0.2) 0 (0) 13 (1) 85 (6.6) 44 (3.4) 16 (1.2) 84 (6.5) 37 (3) 15 (1.2) 21 (1.6) 11 (0.9) 75 (6) 7 (0.5) 28 (2.2) 49 (4) 124 (10) 57 (29) 4 (2) 43 (22) 0 (0) 2 (1) 8 (4) 34 (17) 23 (12) 9 (4.6) 11 (5.6) 1 (0.5) 1 (0.5) 0 (0) 1 (0.5) 9 (4.6) 7 (3.6) 2 (1) 28 (14) 19 (10) 2 (1) 1 (0.5) 6 (3) 9 (4.6) 1 (0.5) 3 (2) 8 (4) 16 (8) 17 (33) 1 (2) 12 (24) 0 (0) 1 (2) 3 (6) 10 (20) 10 (20) 5 (10) 5 (10) 0 (0) 0 (0) 0 (0) 0 (0) 2 (4) 1 (2) 2 (4) 1 (2) 1 (2) 0 (0) 0 (0) 0 (0) 1 (2) 2 (4) 0 (0) 3 (6) 2 (4) 19 (17) 2 (2) 12 (11) 0 (0) 1 (1) 4 (4) 11 (10) 18 (16) 8 (7) 4 (4) 0 (0) 0 (0) 3 (3) 3 (3) 3 (3) 2 (2) 2 (2) 10 (9) 0 (0) 0 (0) 8 (7) 2 (2) 5 (4.5) 0 (0) 26 (24) 5 (4.5) 9 (8) 58 (18) 9 (3) 44 (14) 0 (0) 1 (0.3) 4 (1) 108 (33) 34 (10) 15 (5) 14 (4) 3 (1) 0 (0) 0 (0) 2 (0.6) 16 (5) 8 (2.5) 4 (1) 19 (6) 8 (2.5) 4 (1) 3 (1) 4 (1) 16 (5) 0 (0) 5 (1.5) 23 (7) 34 (10) 707 (28) – – – – – 399 (16) 298 (12) – – – – – – 148 (6) 86 (3) 33 (1) 151 (6) – – – – 150 (6) 17 (0.7) 172 (7) 101 (4) 224 (9) * Values are the number (%) of patients. See Table 1 for definitions. the general population, by 0.6 to 4.3 times. The age- and sex-adjusted SMR was highest for SLE (5.3), SSc (3.9), and SV (2.6). For women, the loss in life expectancy at birth was greatest for patients with SSc (34 years), SV (19 years), and SLE (20 years). For men, the loss in life expectancy was greatest for patients with SV (28 years), SLE (27 years), and SSc (16 years). The most common cause of death in all of the diseases studied was infection, followed by cardiovascular complications, malignancies, and uncontrolled disease activity. The loss in life expectancy in patients with rheumatic diseases, especially during the early years of life, is an important issue because it causes a tremendous loss of economic productivity in the community. Although there have been a number of previous studies of cumulative survival rates in patients with these rheumatic diseases, not many studies focusing on ageadjusted mortality rates compared to the general population have been published. A PubMed search revealed 6 studies of SMRs in SLE patients, 12 in RA patients, 3 in PsA patients, 3 in SSc patients, and 3 in SV patients (9,13–38). There was only one study on SMR in AS patients, published in 1993 (39). The reported unad- justed SMRs for RA and SLE ranged from 1.15 to 2.64 (17–28) and from 2.17 to 3.81 (9,13–17), respectively. SSc had the highest SMR, with results ranging from 1.46 to 4.29 (33–35). The SMR of antineutrophil cytoplasmic antibody–associated vasculitis ranged from 1.60 to 4.80 (36–38). The SMR of PsA patients was reported to be 1.62 in a cohort from the 1980s (32), but the SMR determined in the past decade was reported to be 0.56–0.82, i.e., not higher than that of the general population (30,31). Table 4 summarizes the SMRs for different rheumatic diseases found in different studies. The SMRs for the patients with SLE and SSc in the present study were similar to those found in patients from most other geographic areas. The SMR for patients with PsA in the present study was 2.50, and the mortality rate was significantly higher than that of the general population. The SMRs for patients with RA, AS, and SV in the present study were higher than those reported in the literature. After adjustment for age and sex, the SMRs for these 3 diseases ranged from 1.68 to 2.64. The reasons for the discrepancies in the SMRs between patients with RA, AS, and SV in the present study and LIFE EXPECTANCY, SMRs, AND CAUSES OF DEATH IN RHEUMATIC DISEASES 1187 Table 4. Standardized mortality ratios for various rheumatic diseases determined in the past decade* Author, year (ref.) SLE Present study Hersh et al, 2010 (13) Urowitz et al, 2008 (14) Mok et al, 2008 (9) No. of patients 5,686 957 389 442 Bernatsky et al, 2006 (15) Chun and Bae, 2005 (16) Bjornadal et al, 2004 (17) RA Present study 9,547 434 (women) 4,737 Nakajima et al, 2010 (18) Bergstrom et al, 2009 (19) Young et al, 2007 (20) Gonzalez, 2007 (21) Sihvonen et al, 2004 (22) Minaur et al, 2004 (23) Thomas et al, 2003 (24) Male Female Gabriel et al, 2003 (25) Bjornadal et al, 2002 (26) Gordon, 2001 (27) Martinez et al, 2001 (28) Chehata et al, 2001 (29) PsA Present study 7,926 161 1,429 822 1,042 100 41,344 Buckley et al, 2010 (30) Ali et al, 2007 (31) Wong et al, 1997 (32) SSc Present study Hissaria et al, 2010 (33) Ioannidis et al, 2005 (34) Simeon et al, 2003 (35) AS Present study Lehtinen, 1993 (39) SV Present study Eriksson et al, 2009 (36) Mohammad et al, 2009 (37) Lane et al, 2005 (38) 9,469 609 61,899 289 182 309 822 453 680 428 547 786 1,645 79 2,322 398 1,907 63 (MPA/WG) 140 (MPA/WG/CSS) 99 (MPA/WG/CSS) Country SMR (95% CI) Study period Hong Kong, China US Canada Hong Kong, China Multinational Korea Sweden 2.63 (2.41–2.86) 1999–2008 2.5 (2.0–3.2) 3.81 (1.98–7.32) 2.17 (0.7–6.7) 2002–2007 1997–2005 2000–2006 2.4 (2.3–2.5) 3.02 (1.45–5.55) 3.63 (3.49–3.78) 1970–2001 1992–2001 1964–1995 Hong Kong, China Japan Sweden UK US Finland UK UK 4.58 (4.33–4.83) 1999–2008 1.46 to 1.90 1.15 (0.82–1.60) 1.27 (1.04–1.46) 1.35 (1.23–1.49) 2.64 (2.63–2.68) 2.13 (1.26–3.60) 2000–2007 1995–2002 1986–1997 1965–2005 1988–1999 1957–1999 1981–2000 2.07 (2.01–2.13) 1.97 (1.93–2.01) 1.27 (1.13–1.41) 2.03 (2.00–2.05) 1.30 (1.08–1.56) 1.85 1.65 (1.34–1.98) 1955–1994 1964–1995 1986–1996 1989–1998 1981–1998 Hong Kong, China UK Canada Canada 2.50 (1.81–3.19) 1999–2008 0.82 (0.58–1.13) 0.56 (0.14–2.25) 1.62 (1.21–2.12) 1985–2007 1996–2004 1978–1994 Hong Kong, China Australia Multinational Spain 7.29 (5.93–8.65) 1999–2008 1.46 (1.28–1.69) 1.5 to 7.2 4.29 (2.22–7.50) 1993–2007 1982–1995 1976–1996 Hong Kong, China Finland 3.07 (2.64–3.50) 1999–2008 1.5 1961–1993 Hong Kong, China Sweden Sweden UK 6.47 (5.77–7.18) 1999–2008 1.6 (0.6–3.2) 2.77 (2.02–3.71) 4.8 (3.0–6.6) 1997–2005 1997–2006 1988–2000 US Sweden UK Spain UK * SMR ⫽ standardized mortality ratio; 95% CI ⫽ 95% confidence interval; MPA ⫽ microscopic polyangiitis; WG ⫽ Wegener’s granulomatosis; CSS ⫽ Churg-Strauss syndrome (see Table 1 for other definitions). those in previous studies are open to speculation. Undercoding of RA and AS in the present study was more likely to occur, since most patients are seen and treated in the outpatient and day-ward setting. In the present study, SV included all types of vasculitis as judged by the attending physician, including paraneoplastic vasculitis. This might have caused a higher mor- tality rate compared to those reported for antineutrophil cytoplasmic antibody–associated vasculitis. The causes of death in patients with the 6 rheumatic diseases investigated in this study were consistent with those found in most previous studies (13–39). Infections remained the most common immediate cause of death. This was the result of immunomodulatory 1188 therapies and the intrinsic immune aberrations of the diseases themselves, causing an increased susceptibility to invasion by microorganisms. Chronic inflammation leading to persistent elevation of cytokine levels, which is central to rheumatic disease activity, accelerates atherosclerosis in addition to traditional Framingham risk factors. This explains the contribution of cardiovascular and cerebrovascular complications as an important cause of death in these diseases. Uncontrolled or refractory disease manifestations, particularly for some diseases such as SSc, SLE, and SV, lead to organ damage and account for the decreased survival. On the other hand, the long-term use of immunosuppressive agents and defective immune surveillance increases the risk of malignancies, which is another important cause of death in rheumatic diseases. Finally, it should be noted that while the factors that contribute to mortality mentioned above are disease-related, other factors, such as genetic background, environment, cultural beliefs, smoking, alcohol abuse, education level, socioeconomic status, medical and specialist referral system, delay in seeking medical advice, availability of immunization programs, and compliance with treatment are also involved. This may also explain the discrepancies in the mortality rates of the same group of diseases observed in different geographic areas. The present study has some limitations. First, this is a study derived from data obtained from a hospital registry. Undercoding of the diagnoses among patients is bound to occur, whereas the number of deaths recorded in the registry is accurate and mandatory. This could have led to an underestimation of the total number of patients with the 6 diseases studied and subsequent overestimation of the SMRs. Second, as with all registry studies, the accuracy of the clinical diagnosis as judged by the attending physician cannot be verified. Third, we incorporated some assumptions into the calculation of the mortality ratios and life expectancy, such as uniform distribution of the number of deaths within the age ranges. Finally, since the hospital registry data management system only became available in the late 1990s, we did not have data on the trend of these mortality statistics in the last decade compared to two decades ago. Nevertheless, this is the first study to describe the mortality statistics for various chronic rheumatic diseases in our geographic area. This serves as an important reference for future survival analysis and epidemiology surveys in our community and in the field of rheumatology. MOK ET AL ACKNOWLEDGMENTS The authors would like to thank all of the rheumatologists and physicians working in public hospitals in Hong Kong who contributed to the management of patients with rheumatic diseases within the study period. We would also like to thank the Hospital Authority headquarters staff members who are responsible for maintaining the CDARS data system. Without this system and their technical support, this study would not have been successful. AUTHOR CONTRIBUTIONS All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Mok had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design. Mok, Kwok, Ho, Chan, Yip. Acquisition of data. Mok, Kwok, Ho, Chan, Yip. Analysis and interpretation of data. Mok, Kwok, Ho, Chan, Yip. REFERENCES 1. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7:R634–43. 2. Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, Sokka T, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009;61:1580–5. 3. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pineiro A, Garcia-Porrua C, Miranda-Filloy JA, et al. HLA–DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:125–32. 4. Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis 2010;103:253–61. 5. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167–72. 6. Mok CC, Ho LY, To CH. Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus. Scand J Rheumatol 2009;38:362–8. 7. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131–5. 8. Mok CC, Mak A, Chu WP, To CH, Wong SN. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore) 2005; 84:218–24. 9. Mok CC, To CH, Ho LY, Yu KL. Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. J Rheumatol 2008;35:1978–82. 10. Andersen PK, Borgan O, Gill RD, Keiding N. Statistical models based on counting processes. New York: Springer-Verlag; 1993. p. 322. 11. Preston SH, Heuveline P, Guillot M. Demography: measuring and modeling population processes. Oxford (UK): Blackwell; 2009. p. 38–70. 12. Agresti A. Categorical data analysis. New York: John Wiley & Sons; 1990. p. 40. 13. Hersh AO, Trupin L, Yazdany J, Panopalis P, Julian L, Katz P, et LIFE EXPECTANCY, SMRs, AND CAUSES OF DEATH IN RHEUMATIC DISEASES 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:1152–9. Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008;35:2152–8. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550–7. Chun BC, Bae SC. Mortality and cancer incidence in Korean patients with systemic lupus erythematosus: results from the Hanyang lupus cohort in Seoul, Korea. Lupus 2005;14:635–8. Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95. J Rheumatol 2004;31:713–9. Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 2010;39:360–7. Bergstrom U, Jacobsson LT, Turesson C. Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmö, Sweden. Rheumatology (Oxford) 2009;48:1600–5. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Early Rheumatoid Arthritis Study (ERAS) group. Mortality in rheumatoid arthritis: increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007;46:350–7. Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM III, Therneau TM, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56:3583–7. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004;33: 221–7. Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ. Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol Suppl 2004;69:3–8. Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 2003;30:958–65. Gabriel SE, Crowson CS, Maradit Kremers H, Doran MF, Turesson C, O’Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54–8. 1189 26. Bjornadal L, Baecklund E, Yin L, Granath F, Klareskog L, Ekbom A. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol 2002;29:906–12. 27. Gordon P, West J, Jones H, Gibson T. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. J Rheumatol 2001;28:2409–15. 28. Martinez MS, Garcia-Monforte A, Rivera J. Survival study of rheumatoid arthritis patients in Madrid (Spain): a 9-year prospective follow-up. Scand J Rheumatol 2001;30:195–8. 29. Chehata JC, Hassell AB, Clarke SA, Mattey DL, Jones MA, Jones PW, et al. Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) 2001;40:447–52. 30. Buckley C, Cavill C, Taylor G, Kay H, Waldron N, Korendowych E, et al. Mortality in psoriatic arthritis—a single-center study from the UK. J Rheumatol 2010;37:2141–4. 31. Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 2007;56:2708–14. 32. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40: 1868–72. 33. Hissaria P, Lester S, Hakendorf P, Woodman R, Patterson K, Hill C, et al. Survival in scleroderma: results from the population based south Australian register. Intern Med J 2010. E-pub ahead of print. 34. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2–10. 35. Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003;42:71–5. 36. Eriksson P, Jacobsson L, Lindell A, Nilsson JA, Skogh T. Improved outcome in Wegener’s granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J Intern Med 2009;265:496–506. 37. Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 2009;48:1560–5. 38. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM 2005;98:97–111. 39. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52: 174–6.